Professor Maya Buch


Deputy Director, Leeds Institute of Rheumatic and Musculoskeletal Medicine

Phone Number

0113 392 3043


Leeds Institute of Rheumatic and Musculoskeletal Medicine
Second Floor
Chapel Allerton Hospital
Harehills Lane


Having obtained her medical qualification from the University of Birmingham, UK, followed by internal medicine training, Prof Buch commenced specialist rheumatology training in Leeds. She completed a PhD and subsequently undertook a Clinical Research Fellowship at the University of Michigan Hospitals Scleroderma Program.

Prof Buch has extensive experience in immunotherapies in autoimmune disease. Her doctoral thesis focused on the investigation and management of differential response to TNF inhibitors in rheumatoid arthritis (RA). Her research programme includes large clinical trial activity with a translational focus; understanding mechanism of action of targeted therapies and identification of response predictors to select appropriate patients for specific therapies. One of her activities includes the lead in a large UK RCT (‘SWITCH’) – a ‘head to head’ study in first TNF inhibitor failures in RA.

Recent international activities include task force participation for the European league Against Rheumatism (EULAR) RA management guidelines and co-lead on the updated rituximab consensus statement. She co-founded EMEUNET, a young rheumatologist’s EULAR initiative and was its first Chair; aimed at promoting education, collaboration and excellence in research by emerging rheumatologists in Europe

Research Interests

Inflammatory Arthritis

Immunotherapies/Biologicals, Clinical trials

Prediction of treatment response, developing treatment algorithms

Systemic sclerosis

Significant Publications


Grants Awarded

DateDescriptionReceived From


UK centre collaborations: ‘SWITCH’ Study, Randomised-controlled trial of switching to alternative tumour-necrosis factor (TNF)-blocking drugs or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-blocking drug: National Institute of Health Research

‘APIPPRA’ Study (Arthritis Prevention In the Preclinical Phase of Rheumatoid Arthritis with Abatacept): Collaboration with Prof. A. Cope, Kings College London (study CI)